1. Scrip
  2. >>R&D

Zygogen LLC

 
• By Mark Ratner

Buoyed by the continuing interest in zebrafish as a model organism for comparative genomics research, Zygogen has developed fluorescent transgenic zebrafish lines it uses to identify and validate new targets and screen drugs.

The inch-long, striped tropical zebrafish (Danio rerio), long a fixture in aquariums, has also evolved over the past ten years to become a staple in comparative genomics—the use of model organisms to identify homologs of human genes linked to disease processes.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from R&D

Revolution’s Next KRAS Drug Shows Promise In NSCLC

 
• By Andrew McConaghie

Already a frontrunner in developing the KRAS G12D inhibitor class, analysts think Revolution Medicine could seal its leadership by combining zoldonrasib with other agents in its portfolio.

Pipeline Watch: Five Approvals And One Phase III Readout

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

GSK: Blenrep’s Return Is Just The Start Of Our Oncology Renaissance

 
• By Andrew McConaghie

GSK’s antibody-drug conjugate looks set for a blockbuster future in multiple myeloma after an approval in the UK, and the company’s head of oncology says it is already planning for the next generation of therapies.

Novotech CEO On Flexible Trial Solutions Amid Tariff, Geopolitical Tensions

 
• By Anju Ghangurde

Novotech's CEO talks about rising interest for trials in regions with “regulatory agility” and “strategic insulation” from geopolitical complexity, especially among emerging and mid-sized biotech sponsors. Operational "reassessment” among some sponsors on exposure to China-based CROs/CRDMOs is another area he discussed.

More from Scrip